Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin
about
Clinical and Laboratory Diagnosis of Buruli Ulcer Disease: A Systematic ReviewThe pathogenic mechanism of the Mycobacterium ulcerans virulence factor, mycolactone, depends on blockade of protein translocation into the ERPhase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial.Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).Experimental infection of the pig with Mycobacterium ulcerans: a novel model for studying the pathogenesis of Buruli ulcer disease.Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?Severe multifocal form of buruli ulcer after streptomycin and rifampin treatment: comments on possible dissemination mechanisms.Histopathological changes and clinical responses of Buruli ulcer plaque lesions during chemotherapy: a role for surgical removal of necrotic tissue?Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection.Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans diseaseThe use of ozone therapy in Buruli ulcer had an excellent outcome.Impact of human immunodeficiency virus on the severity of buruli ulcer disease: results of a retrospective study in cameroon.Immunohistochemical monitoring of wound healing in antibiotic treated Buruli ulcer patients.Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infectionChallenges Associated with Management of Buruli Ulcer/Human Immunodeficiency Virus Coinfection in a Treatment Center in Ghana: A Case Series Study.Local Cellular Immune Responses and Pathogenesis of Buruli Ulcer Lesions in the Experimental Mycobacterium Ulcerans Pig Infection Model.Mycobacterium ulcerans Mouse Model Refinement for Pre-Clinical Profiling of Vaccine Candidates.Assessing and managing wounds of Buruli ulcer patients at the primary and secondary health care levels in Ghana.Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humansBuruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.Susceptibility Profiles of Mycobacterium ulcerans Isolates to Streptomycin and Rifampicin in Two Districts of the Eastern Region of Ghana.Laboratory diagnosis of Buruli ulcer disease.Pathogenesis of skin ulcers: lessons from the Mycobacterium ulcerans and Leishmania spp. pathogens.Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease.Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases.Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans
P2860
Q26740428-087A27C2-CBB3-42C6-B749-E0E987C57AECQ28541949-F87BF988-615A-41A4-AE5E-53284B48DA61Q33409842-14CB0666-632C-4991-8BC0-0E28D4335F52Q33631299-3AD01233-F15C-4A83-83BA-A5E9E6DAEF3EQ33881961-1E25D780-C0D0-4FC3-8258-51AF590BBF76Q33988898-71B5D412-475F-4891-975B-506765FB19E4Q34024822-E5B32AEB-B6A9-4495-91E1-82100FFE987CQ34043539-56C6C335-5072-46C6-B870-54F9DBBF030CQ34484489-0E51D1D0-44C9-44A5-B67D-B844BED54D7CQ34500901-0CAE88F2-13B6-42B4-AF03-0C94F66A5BD9Q34630531-ED90B028-2127-4136-B274-FE26F8B1A8F0Q34647915-C28A4C6D-5898-41AF-B39C-8BA665DA2A55Q35071988-8B2ED15E-7BC5-4E7B-95C3-BDBD466FD394Q35156761-ED5930FE-F583-4565-B480-B2153C92841AQ35625819-2BF08DEF-DF4B-4E8F-9234-C744181FA2DAQ35689285-1BD36134-70CE-40BB-A373-73B84DCCB44FQ35790836-8B2490CD-A730-468F-88F5-8E37F8ED520EQ35933855-C6983391-FE61-4807-A8CB-1C8CCD664B22Q36002996-83B70B5B-126E-486A-B551-65E54FE50E6FQ36205512-C1DDE49D-E496-41D0-9624-99ABA963A977Q36292804-3014D18C-D3AE-40BA-B680-2851E3064534Q37051036-E852B80D-211A-4746-9E90-E169838DA0CBQ37349850-B09A5B3D-2B88-42F0-8812-5C8443B3F49CQ37539074-B5B85AED-4B39-4672-8EE2-2DB2F0075D5EQ37704358-0C4514A0-3607-4977-BAF6-291AD324E852Q38180374-43630480-7513-44D9-B0EF-0CDA19B0E93DQ38634493-6BFA7BBB-1AC2-4242-A2B2-35134F0911CCQ39432050-C3981BC7-BF0D-4442-B044-25EB45A1F0C9Q48176377-2664BF9A-659A-49A8-9D57-BFCB8331D9B2Q57203196-B0F795B7-65A6-4927-A913-91C3CEA0A3DA
P2860
Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Development of highly organize ...... th rifampicin and streptomycin
@ast
Development of highly organize ...... th rifampicin and streptomycin
@en
Development of highly organize ...... th rifampicin and streptomycin
@nl
type
label
Development of highly organize ...... th rifampicin and streptomycin
@ast
Development of highly organize ...... th rifampicin and streptomycin
@en
Development of highly organize ...... th rifampicin and streptomycin
@nl
prefLabel
Development of highly organize ...... th rifampicin and streptomycin
@ast
Development of highly organize ...... th rifampicin and streptomycin
@en
Development of highly organize ...... th rifampicin and streptomycin
@nl
P2093
P2860
P3181
P1476
Development of highly organize ...... th rifampicin and streptomycin
@en
P2093
Alphonse Um-Boock
Daniela Schütte
Ernestina Mensah-Quainoo
Peter Itin
Peter Schmid
P2860
P3181
P356
10.1371/JOURNAL.PNTD.0000002
P407
P577
2007-10-31T00:00:00Z